Skip to main content
REVB logo

REVB · Revelation Biosciences, Inc. · Metrics

Track REVB — free
$3.71 +0.02 (+0.54%)
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20 1858 Avg daily vol (23 sessions) 20.32K

REVB metrics

49 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.69
Market cap
$2.52M

Price action

23 metrics
Price change (1W)
-15.8%
Price change (30D)
+2.5%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$26.57
52-week low
$3.20
Change from 52-week high
-86.1%
Change from 52-week low
+15.3%
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
46.3
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
20,323
Relative volume
0.3
Average dollar volume
$78,444

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
683,442

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 6,085.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.3
reciprocal yield 286.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-482.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$12.71M
Net income (TTM)
−$12.16M
Trailing 12 months
Diluted EPS (TTM)
$224.54
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$39.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+492.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-168.1%
Return on assets
-121.3%
Debt / equity
0.0
Current ratio
4.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.12M
Latest balance sheet
Cash & equivalents
$9.12M
Total assets
$10.02M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.10M
Capital expenditures (TTM)
—
R&D (TTM)
$5.77M
SG&A (TTM)
—
Stock compensation (TTM)
$1.72M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
13
13F filer change QoQ
+1
Institutional ownership
34.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.8%
Private-fund adviser ownership
2.5%
Active holders' share change QoQ
+115.8%
Holder tenure
3.8
Price vs estimated holder cost
-21.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.9%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1810560 CUSIP 76135L887 13F (30d) 16 filings 14 filers Visit website Investor relations